Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 8/20 | 0.38 |
| ▸ | RAB9A | P51151 | 8/20 | 0.36 |
| ▸ | NPC1 | O15118 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16093359 | 0.82 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GCD274PDCD1LG2RAB9A | |
| SCHEMBL13171569 | 0.81 | KDM4E (0.44) | APOBEC3AAPOBEC3GCD274PDCD1LG2RAB9A | |
| SCHEMBL5010358 | 0.80 | CD274 (0.51) | APOBEC3AAPOBEC3GCD274PDCD1LG2RAB9A | |
| SCHEMBL2031694 | 0.80 | KDM4E (0.47) | APOBEC3AAPOBEC3GCD274PDCD1LG2RAB9A | |
| SCHEMBL5781489 | 0.80 | APOBEC3A (0.44) | APOBEC3AAPOBEC3GCD274PDCD1LG2RAB9A | |
| SCHEMBL29555612 | 0.80 | KDM4E (0.47) | APOBEC3AAPOBEC3GCD274PDCD1LG2RAB9A | |
| SCHEMBL23398050 | 0.77 | APOBEC3A (0.42) | APOBEC3AAPOBEC3GCD274PDCD1LG2RAB9A | |
| SCHEMBL23287266 | 0.74 | MBOAT4 (0.45) | CD274PDCD1LG2KDM4EHSD17B10 | |
| SCHEMBL12427065 | 0.73 | HPGD (0.49) | CD274PDCD1LG2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1672587 | 0.72 | RAB9A (0.41) | APOBEC3AAPOBEC3GRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | US | disclosed |
| CN-112543757-A | Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus | 卡迪拉保健有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-8841455-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2516433-B1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2516433-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | Array Biopharma, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2011079076-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | DPEP1, SAT1, PEPD | APOBEC3A 4160/4885APOBEC3G 4509/4885CD274 1195/4885 |
| US-11702404-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | APOBEC3A 4575/4885APOBEC3G 4214/4885CD274 3049/4885 |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | AFF1, FLI1, F3 | APOBEC3A 4666/4885APOBEC3G 4748/4885CD274 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.